Cargando…

Severe hypophosphataemia after intravenous iron administration

Iron deficiency is common and can be effectively treated with parenteral iron infusion. We report a case of an iron-deficient and vitamin D-deficient woman who developed severe symptomatic hypophosphataemia following intravenous ferric carboxymaltose administration. We stress the need of increased a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anand, Gurpreet, Schmid, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353490/ https://www.ncbi.nlm.nih.gov/pubmed/28289000 http://dx.doi.org/10.1136/bcr-2016-219160

Ejemplares similares

Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction
por: Ifie, Eseoghene, et al.
Publicado: (2019)

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Clinical factors associated with severe hypophosphataemia after kidney transplant
por: Ralston, Maximilian R., et al.
Publicado: (2021)

Hypophosphataemia among Severely-malnourished Children: Case Series
por: Yoshimatsu, Shoji, et al.
Publicado: (2012)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

Incidence, severity and timing of hypophosphataemia in Glasgow Royal Infirmary ICU
por: Gilhooly, CJ, et al.
Publicado: (2009)

Isolated hypophosphataemia as an early marker of primary hyperparathyroidism
por: Alexander, John, et al.
Publicado: (2021)

Recurrent severe hypophosphatemia following intravenous iron administration
por: Nataatmadja, Melissa Stephanie, et al.
Publicado: (2020)

Life-threatening hypophosphataemia in a cirrhotic patient with jaundice
por: Moutzouri, Elisavet, et al.
Publicado: (2011)

Left Ventricular Hypertrophy in Patients with X-Linked Hypophosphataemia
por: Castellano-Martinez, Ana, et al.
Publicado: (2022)

Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status
por: Fang, Wendy, et al.
Publicado: (2020)

Perioperative management of patients with severe hypophosphataemia secondary to oncogenic osteomalacia: Our experience and review of literature
por: Verma, Alka, et al.
Publicado: (2017)

Acute onset quadriparesis following oesophagectomy due to isolated hypophosphataemia
por: Naik, Vibhavari M, et al.
Publicado: (2019)

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
por: Haffner, Dieter, et al.
Publicado: (2019)

Hepatic osteodystrophy with hypophosphataemia and elevated fibroblast growth factor‐23
por: Ng, Nicholas Beng Hui, et al.
Publicado: (2022)

Bleomycin-Induced Lung Injury After Intravenous Iron Administration
por: Saccone, Nicole, et al.
Publicado: (2022)

Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies
por: Kubota, Takuo, et al.
Publicado: (2023)

New Developments in the Treatment of X-Linked Hypophosphataemia: Implications for Clinical Management
por: Saraff, Vrinda, et al.
Publicado: (2020)

Correcting hypophosphataemia in a paediatric patient with Sanjad–Sakati syndrome through a single oral dose of potassium phosphate intravenous solution
por: Sabti, Mnaff A, et al.
Publicado: (2021)

Intravenous Iron Administration and Hypophosphatemia in Clinical Practice
por: Hardy, S., et al.
Publicado: (2015)

Intravenous Iron Therapy: Re-administration after Prior Adverse Reaction
por: Aung, Tim, et al.
Publicado: (2023)

Oral health‐related quality of life in X‐linked hypophosphataemia and osteogenesis imperfecta
por: Gjørup, Hans, et al.
Publicado: (2020)

Persistent Severe Hiccups After Dexamethasone Intravenous Administration
por: Sugandhavesa, Nantawit, et al.
Publicado: (2019)

Treatment of hypophosphataemia in critically ill patients with a two day dosing regimen
por: Giles, LJ, et al.
Publicado: (2000)

Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy
por: Godaly, Gabriela, et al.
Publicado: (2016)

Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review
por: Seefried, L., et al.
Publicado: (2020)

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
por: Kamenicky, Peter, et al.
Publicado: (2023)

Intravenous Iron Induced Severe Hypophosphatemia
por: Guo, Rong R, et al.
Publicado: (2021)

Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials
por: Rosano, Giuseppe MC, et al.
Publicado: (2023)

Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures
por: Nathell, Lennart, et al.
Publicado: (2019)

Administration of Intravenous Iron Formulations Induces Complement Activation in-vivo
por: Faria, Bernardo, et al.
Publicado: (2019)

Ventricular bigeminy and trigeminy caused by hypophosphataemia during diabetic ketoacidosis treatment: a case report
por: Miszczuk, Konrad, et al.
Publicado: (2019)

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial‐IRON Trial
por: Núñez, Julio, et al.
Publicado: (2020)

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
por: Zoller, Heinz, et al.
Publicado: (2023)

Comment on ‘Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures’
por: Schaffalitzky de Muckadell, Philip, et al.
Publicado: (2020)

A case of intravenous iron administration resulting in cerebral edema expansion
por: Espinosa, Jonathan, et al.
Publicado: (2023)

The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study
por: Padidela, Raja, et al.
Publicado: (2020)

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
por: Seefried, Lothar, et al.
Publicado: (2023)

Intravenous Iron Therapy in a Case of Severe Anæmia after Pregnancy and Childbirth
por: Chatterjee, P. K., et al.
Publicado: (1952)

Cannot write session to /tmp/vufind_sessions/sess_g60072k4hk8uf2dnnos9f2bikp